Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

UK Health Body Approves Novartis's Tasigna For CML

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/25/2012 | 01:16am CEST

The U.K.'s health-cost regulator has decided to back an expensive cancer drug from Novartis AG (NVS) for treating chronic myeloid leukemia--but not one from U.S.-based Bristol-Myers Squibb Co. (BMY)--after the Swiss drug maker offered to cut the drug's price.

The independent National Institute for Clinical Excellence, known by its acronym NICE, said Wednesday it approved Novartis's Tasigna and the company's older drug, whose brand name is Glivec, for use in treating CML on the publicly funded National Health Service. The generic names for Tasigna and Glivec are nilotinib and imatinib, respectively.

However, NICE said it wasn't approving Bristol-Myers Squibb's Sprycel, also known as dasatinib.

CML is a cancer of blood-forming cells in the bone marrow that usually develops slowly, which is why it is described as a chronic form of the disease.

NICE director Carole Longson said: "The recommendations reaffirm the use of imatinib as an effective treatment for the majority of patients and a cost-effective use of NHS resources, and we are also very pleased to be able to add a further treatment option for these patients by recommending nilotinib.

"Although no trials directly comparing dasatinib and nilotinib were available, the committee concluded from indirect comparisons that dasatinib and nilotinib could be considered equally as effective in treating CML.

"However, the manufacturer of nilotinib has already agreed with the Department of Health to provide the drug to the NHS at a discounted price. This reduction in cost enabled the independent committee to approve nilotinib for use on the NHS."

Dasatinib and nilotinib both cost over GBP30,000 per patient a year and the standard dose of imatinib costs GBP20,000.

NICE didn't disclose the price discount offered by Novartis for nilotinib.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
09:14a NOVARTIS : Sandoz receives approval in Europe for Erelzi® (biosimilar etanercept..
06/26 NOVARTIS : Health and Human Services Department (HHS); Food and Drug Administrat..
06/23 PFIZER : Global Latanoprost Sales Market 2017 - Pfizer, Jamp Pharma, Laboratoire..
06/23 NOVARTIS : NEJM publishes full analysis of Rydapt® (midostaurin) Phase III RATIF..
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/23 HERE’S WHAT’S MOVING NOV : NVS) and Kamada Ltd (NASDAQ:KMDA)
06/23 NOVARTIS : Kisqali® (ribociclib) receives positive CHMP opinion as first-line tr..
06/23 NOVARTIS : data shows half of eligible Ph+ CML-CP patients remain in Treatment-f..
06/23 NOVARTIS : pivotal CTL019 6-month follow-up data show durable remission rates in..
06/22 NOVARTIS : combination targeted therapy Tafinlar® + Mekinist® receives FDA appro..
More news
Sector news : Pharmaceuticals - NEC
07:35pDJMERCK AND : Says Its Network Was Hit by Global Hack
06/26DJASTRAZENECA : ADRs End Mostly Higher
06/26 VALEANT PHARMACEUTICALS INTL : Hedge fund Paulson & Co discloses 6.3 percent sta..
06/26DJHow Third Point's Nestlé Move Could Affect L'Oréal
06/23DJSAMSUNG ELECTRONICS : Makes Play for Drug Market With Version of Humira -- Updat..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02:08p Kala Pharmaceuticals Files For $86 Million IPO
12:41p CAR-T Value Calculation In The Firing Line
10:30a 3 THINGS IN BIOTECH YOU SHOULD LEARN : June 27, 2017
07:56a Putting A Number On CAR-T Deaths
06/26 THE OPIOID ABUSE EPIDEMIC : What's The Investment Angle?
Advertisement
Financials ($)
Sales 2017 48 383 M
EBIT 2017 11 853 M
Net income 2017 7 439 M
Debt 2017 15 455 M
Yield 2017 3,30%
P/E ratio 2017 25,77
P/E ratio 2018 22,70
EV / Sales 2017 4,97x
EV / Sales 2018 4,75x
Capitalization 225 157 M
More Financials
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 82,4 $
Spread / Average Target -3,9%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS12.96%225 386
JOHNSON & JOHNSON18.42%367 520
ROCHE HOLDING LTD.8.68%224 497
PFIZER4.80%203 487
MERCK AND COMPANY11.98%180 958
SANOFI15.34%123 860
More Results